News Sentiment

VNDA sentiment intelligence

Vanda Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 6.24 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+0.5% over one week, +6.3% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Has Vanda Pharmaceuticals Finally Found Its Game-Changer with Bysanti

Market Reaction

Balanced read

49/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction 0.5% Price digesting
Trend fit Trend inactive 6.3% over four weeks
Fair value 20.8% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 38
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 8
Market source 7
simplywall.st 6
Stock Titan 5
Stocktwits 5
TradingKey 5
PR Newswire 4
MarketBeat 2

Event Lens

What the news is about

Classified themes
Market update 27
Earnings 22
Regulatory and legal 4
Deals and strategy 2
Analyst action 2
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 58
Quantisnow Direct company coverage

Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S

Vanda Pharmaceuticals announced that its investigational therapy for Charcot-Marie-Tooth Disease Type 2S has received Rare Pediatric Disease Designation from the FDA. This news was delivered via Quantisnow's real-time market data platform. The designation highlights the potential

Tone
Positive 71/100
Event
Regulatory and legal
Published
08 Jul 2026 10:41
Source
Quantisnow
GuruFocus Direct company coverage

Vanda Pharmaceuticals (VNDA) Receives FDA Rare Pediatric Disease Designation

Vanda Pharmaceuticals (VNDA) has received FDA Rare Pediatric Disease Designation for VCA-894A, an experimental therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S). This designation is a critical step for addressing the rare genetic disorder and could lead to a priori

Tone
Positive 71/100
Event
Market update
Published
07 Jul 2026 21:51
Source
GuruFocus
Stocktwits Direct company coverage

VNDA Stock Gains After-Hours As FDA Grants Rare Pediatric Disease Designation For Experimental Therapy

Vanda Pharmaceuticals (VNDA) saw its stock rise after-hours following the FDA's granting of Rare Pediatric Disease Designation for VCA-894A, its experimental treatment for Charcot-Marie-Tooth disease type 2S. This designation could make Vanda eligible for a priority review vouche

Tone
Positive 73/100
Event
Market update
Published
07 Jul 2026 20:22
Source
Stocktwits
AD HOC NEWS Direct company coverage

Vanda Pharmaceuticals updates investors on business outlook as shares trade in the U.S. market

Vanda Pharmaceuticals, a U.S.-based biopharmaceutical company, continues to develop treatments in neurology, psychiatry, and sleep medicine, with its shares trading on the American market. The company focuses on specialty prescription drugs, generating revenue from approved thera

Tone
Neutral 50/100
Event
Earnings
Published
07 Jul 2026 17:11
Source
AD HOC NEWS
Finviz Direct company coverage

VNDA - Vanda Pharmaceuticals Inc Volatility & Greeks

This article provides a detailed overview of Vanda Pharmaceuticals Inc. (VNDA), including its latest stock performance, key financial metrics, volatility, and options Greeks. It covers market capitalization, recent earnings data, insider and institutional ownership, and various p

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 00:41
Source
Finviz
McDermott Will & Schulte Direct company coverage

McDermott Represents Vanda Pharmaceuticals Inc. on Acquisition of PONVORY®

McDermott Will & Emery represented Vanda Pharmaceuticals Inc. in its acquisition of US and Canadian rights to PONVORY®, a treatment for relapsing forms of multiple sclerosis. The McDermott deal team was led by Kristian Werling with support from numerous other attorneys. This acqu

Tone
Positive 71/100
Event
Deals and strategy
Published
03 Jul 2026 21:41
Source
McDermott Will & Schulte
Insider Monkey Direct company coverage

Here’s Why H.C. Wainwright Remains a Buy on Vanda Pharmaceuticals (VNDA)

H.C. Wainwright has reiterated a Buy rating for Vanda Pharmaceuticals (VNDA) with a $21 price target, following an update on the company's FDA approval process for HETLIOZ as a jet lag treatment. The FDA has granted Vanda a formal hearing, a rare event, to discuss the drug's appr

Tone
Positive 65/100
Event
Analyst action
Published
03 Jul 2026 13:40
Source
Insider Monkey
www.marketscreener.com Direct company coverage

Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Defensive Index

Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) has been removed from the Russell 2000 Defensive Index. This news comes amidst other recent updates for the biopharmaceutical company, including its Q1 2026 earnings call, raising its full-year 2026 revenue guidance, and the U.S. commerc

Tone
Negative 31/100
Event
Earnings
Published
29 Jun 2026 18:11
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Value-Defensive Index

Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) has been removed from the Russell 2000 Value-Defensive Index. This announcement follows several recent company updates, including its Q1 2026 earnings call, raised revenue guidance, and the U.S. launch of its motion sickness drug Nereus.

Tone
Negative 29/100
Event
Earnings
Published
29 Jun 2026 07:39
Source
www.marketscreener.com
TradingView Direct company coverage

Price to book forward of Vanda Pharmaceuticals Inc. – NASDAQ:VNDA

This article provides financial information for Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), specifically focusing on its "Price to book forward" metric. It appears to be a financial data snippet from TradingView, indicating market closed status and offering an overview of financia

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 07:40
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Vanda Pharmaceuticals Inc. – FWB:VM4

This article provides financial information for Vanda Pharmaceuticals Inc. (FWB:VM4), specifically focusing on its price-to-earnings forward ratio. The content lists the company's stock exchange details, and indicates that the market was closed with no trades recorded at the time

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 06:11
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Vanda Pharmaceuticals Inc. – NASDAQ:VNDA

This article provides the "Price to earnings forward" value for Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), indicating it's a financial metric available on TradingView. The content primarily focuses on presenting this specific data point for the company, accessible through its fin

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 05:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBITDA forward of Vanda Pharmaceuticals Inc. – FWB:VM4

The article presents the Enterprise Value to EBITDA forward for Vanda Pharmaceuticals Inc. (FWB:VM4) on the Frankfurt Stock Exchange. It provides financial data for this specific metric and indicates that the market was closed with no trades at the time of publication. The conten

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 03:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Vanda Pharmaceuticals Inc. – LSX:A0JJT3

This article focuses on the "Enterprise value to revenue forward" metric for Vanda Pharmaceuticals Inc. (LSX:A0JJT3). It is presented within the context of financial data available on TradingView, specifically under the company's financials section. The content primarily lists an

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 19:40
Source
TradingView
Barchart.com Direct company coverage

Gastroparesis Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharma, Ironwood Pharma, Takeda

This report from DelveInsight highlights the Gastroparesis treatment pipeline for 2026, detailing over 10 therapies from 8+ companies including CinDome Pharma, Evoke Pharma, and Vanda Pharmaceuticals. The report provides an overview of clinical trials, mechanisms of action, and r

Tone
Positive 66/100
Event
Regulatory and legal
Published
26 Jun 2026 13:39
Source
Barchart.com
MarketBeat Direct company coverage

Vanda Pharmaceuticals (VNDA) Short Interest & Short Float | Updated Jun 2026

Vanda Pharmaceuticals (VNDA) saw a 2.61% increase in its short interest, reaching 6.99 million shares sold short as of June 15, 2026, representing 13.01% of its public float. The short interest ratio is currently 7.8 days to cover, suggesting it would take approximately 7.8 days

Tone
Negative 38/100
Event
Market update
Published
26 Jun 2026 06:40
Source
MarketBeat
TradingView Direct company coverage

Vanda Pharmaceuticals Inc. Actuals & Estimates (NASDAQ:VNDA)

This article provides an overview of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) stock performance, financials, and analyst forecasts. It covers key metrics like current price, market capitalization, earnings, revenue, and future price predictions from analysts, along with historic

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 17:40
Source
TradingView
Stocktwits Direct company coverage

VNDA Stock Rallies After-Hours As FDA Approves Schizophrenia, Bipolar Disorder Drug

Vanda Pharmaceuticals Inc. (VNDA) shares jumped 38% after hours following FDA approval of its Bysanti tablets for treating manic or mixed episodes associated with bipolar I disorder and schizophrenia in adults. Bysanti is expected to be available in Q3 2026 and is also being test

Tone
Positive 91/100
Event
Regulatory and legal
Published
25 Jun 2026 17:10
Source
Stocktwits
Stocktwits Direct company coverage

Vanda Now Looks To Public Hearing For Hetlioz In Jet Lag Disorder After Multiple FDA Rejections

Vanda Pharmaceuticals has secured a formal evidentiary public hearing from the FDA to review the refusal of its supplemental new drug application for Hetlioz in treating jet lag disorder. This is a rare move by the FDA, as such hearings for drug approvals have not been granted in

Tone
Negative 39/100
Event
Market update
Published
25 Jun 2026 05:10
Source
Stocktwits
TradingKey Direct company coverage

Vanda Pharmaceuticals Inc (VNDA) Valuation: PE, PB & Fair Value Analysis

Vanda Pharmaceuticals Inc (VNDA) currently holds a valuation score of 7.67, placing it 211th out of 389 companies in the Biotechnology & Medical Research industry. Its P/E ratio is -1.48, which is significantly below its recent high and above its recent low. Key valuation metrics

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 09:09
Source
TradingKey
TradingKey Direct company coverage

Vanda Pharmaceuticals Inc (VNDA) Financial Health: Profitability & Balance Sheet Analysis

Vanda Pharmaceuticals Inc (VNDA) currently holds a financial score of 7.53, placing it 110th in the Biotechnology & Medical Research industry. Despite a weak financial status overall, the company shows high operating efficiency, with its latest quarterly revenue increasing by 3.3

Tone
Positive 62/100
Event
Earnings
Published
23 Jun 2026 07:09
Source
TradingKey
George Washington University Athletics Direct company coverage

GW Athletics Names Vanda Pharmaceuticals First Official Jersey Patch Partner

GW Athletics has announced a landmark partnership with Vanda Pharmaceuticals, making it the first official jersey patch partner in the program's history. This agreement, the largest corporate partnership for GW Athletics, will feature the Vanda logo on all 20 Revolutionaries team

Tone
Positive 74/100
Event
Deals and strategy
Published
22 Jun 2026 17:09
Source
George Washington University Athletics